Department of Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 83%
3. Radiotherapy 82%
4. Survival 59%
5. Denmark 55%
6. Therapeutics 50%
7. Drug Therapy 44%
8. Patient Reported Outcome Measures 39%
9. Quality of Life 37%
10. Recurrence 37%
11. Glioblastoma 33%
12. Ovarian Neoplasms 32%
13. Population 32%
14. Palliative Care 31%
15. Confidence Intervals 30%
16. Randomized Controlled Trials 30%
17. Head and Neck Neoplasms 29%
18. Cohort Studies 29%
19. Progression-Free Survival 28%
20. Glioma 27%
21. Prostatic Neoplasms 27%
22. Systematic Reviews 26%
23. Cancer Survivors 26%
24. Testicular Neoplasms 23%
25. Non-Small Cell Lung Carcinoma 23%
26. Lung Neoplasms 22%
27. niraparib 20%
28. Safety 20%
29. Registries 20%
30. Squamous Cell Carcinoma 19%
31. ARRY-470 19%
32. Meta-Analysis 18%
33. Guidelines 17%
34. Radiation 17%
35. Exercise 17%
36. Depression 17%
37. Positron-Emission Tomography 17%
38. Urinary Bladder Neoplasms 17%
39. 64Cu-DOTATATE 16%
40. Hodgkin Disease 16%
41. Fluorodeoxyglucose F18 16%
42. Clinical Trials 16%
43. Lymphoma 16%
44. Neoplasm Metastasis 15%
45. Incidence 15%
46. Brain Neoplasms 15%
47. Platinum 14%
48. Squamous Cell Carcinoma of Head and Neck 14%
49. Young Adult 14%
50. Immunotherapy 14%
51. Trastuzumab 14%
52. Pediatrics 13%
53. Caregivers 13%
54. Positron Emission Tomography Computed Tomography 13%
55. Opioid Analgesics 13%
56. Proton Therapy 13%
57. Biomarkers 13%
58. Mortality 12%
59. Germ Cell and Embryonal Neoplasms 12%
60. Placebos 12%
61. Tumor Burden 12%
62. Poly(ADP-ribose) Polymerase Inhibitors 12%
63. Urokinase Plasminogen Activator Receptors 11%
64. Survivors 11%
65. Melanoma 11%
66. Breast 11%
67. Cisplatin 11%
68. Databases 11%
69. Anxiety 11%
70. tropomyosin kinase 11%
71. Fatigue 11%
72. Estrogen Receptors 10%
73. Carcinoma 10%
74. Organs at Risk 10%
75. Feasibility Studies 10%
76. Neurofibromatosis 1 10%
77. Child 10%
78. Pain 10%
79. Oropharyngeal Neoplasms 10%
80. gemcitabine 10%
81. Bevacizumab 9%
82. Testicular Germ Cell Tumor 9%
83. Uterine Cervical Neoplasms 9%
84. Circulating Tumor DNA 9%
85. Radiosurgery 9%
86. Lung 9%
87. Protons 9%
88. Adjuvant Chemotherapy 9%
89. Mutation 9%
90. Health 9%
91. Medical Oncology 9%
92. Letrozole 9%
93. Prospective Studies 9%
94. Disease-Free Survival 8%
95. Tumor-Infiltrating Lymphocytes 8%
96. Odds Ratio 8%
97. Radiation Oncology 8%
98. Comorbidity 8%
99. Carboplatin 8%
100. Deep Learning 8%